Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Guggenheim Securities downgraded GSK to neutral from buy on Thursday after ... most of its cancer claims related to its heartburn drug Zantac in the U.S. and an attractive valuation, “we see ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK (LSE: GSK) shares fell 3.4% to 1,401p ... $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged.

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its discontinued version of the heartburn drug Zantac caused cancer. It took a ...